» Articles » PMID: 30870006

Long Noncoding RNA CDKN2B-AS1 Interacts with Transcription Factor BCL11A to Regulate Progression of Cerebral Infarction Through Mediating MAP4K1 Transcription

Overview
Journal FASEB J
Specialties Biology
Physiology
Date 2019 Mar 15
PMID 30870006
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The effective therapeutic approach of cerebral infarction is limited because of its underlying complexity. Recently, multiple long noncoding RNAs (lncRNAs) have been identified in the pathogenesis of cerebral infarction. Here, the current study aims to explore the interaction among lncRNA cyclin-dependent kinase inhibitor-2B-antisense RNA 1 (CDKN2B-AS1), transcription factor B-cell lymphoma/leukemia 11A (BCL11A), and MAPKK kinase kinase 1 (MAP4K1) and further investigate whether they affect cerebral infarction progression. The expression of CDKN2B-AS1, BCL11A, and MAP4K1 was altered in lymphocytes extracted from patients with cerebral infarction. In order to identify their roles in regulatory T (T) cells, the proliferation and apoptosis of the CD4CD25 T cells were examined, and levels of IL-4, IL-10, and TGF-β were determined. Also, the RNA crosstalk among CDKN2B-AS1, BCL11A, and MAP4K1 was validated. Finally, we established a rat model of middle cerebral arterial occlusion to evaluate the neurologic impairment and cerebral infarction volume. The results revealed that lymphocytes in patients with cerebral infarction presented with the up-regulated expression of CDKN2B-AS1. Moreover, BCL11A could specifically bind to CDKN2B-AS1 and MAP4K1 promoter so as to inhibit MAP4K1. Moreover, it was observed that down-regulated CDKN2B-AS1 inhibited CD4CD25 T-cell proliferation, reduced levels of IL-4, IL-10, and TGF-β and cerebral infarction volume, and elevated MAP4K1 expression. Collectively, our study provides evidence that CDKN2B-AS1 silencing could increase MAP4K1 expression to inhibit the CD4CD25 T-cell proliferation by reducing enrichment of transcription factor BCL11A, thereby protecting against cerebral infarction progression, highlighting a promising therapeutic strategy for treating cerebral infarction.-Lei, J.-J., Li, H.-Q., Mo, Z.-H., Liu, K.-J., Zhu, L.-J., Li, C.-Y., Chen, W.-L., Zhang, L. Long noncoding RNA CDKN2B-AS1 interacts with transcription factor BCL11A to regulate progression of cerebral infarction through mediating MAP4K1 transcription.

Citing Articles

Gene Commonality in Arterial Circuits Throughout the Body.

Harling L, Zafar M, Ziganshin B, Elefteriades J Aorta (Stamford). 2024; 12(1):8-12.

PMID: 39532283 PMC: 11606663. DOI: 10.1055/s-0044-1791667.


Mutual Regulation of ncRNAs and Chromatin Remodeling Complexes in Normal and Pathological Conditions.

Bure I, Nemtsova M Int J Mol Sci. 2023; 24(9).

PMID: 37175555 PMC: 10178202. DOI: 10.3390/ijms24097848.


Long non-coding RNA lincRNA-erythroid prosurvival (EPS) alleviates cerebral ischemia/reperfusion injury by maintaining high-temperature requirement protein A1 (Htra1) stability through recruiting heterogeneous nuclear ribonucleoprotein L (HNRNPL).

Guo H, Guo X, Jiang S Bioengineered. 2022; 13(5):12248-12260.

PMID: 35549989 PMC: 9275866. DOI: 10.1080/21655979.2022.2074738.


NCK1-AS1 promotes the progression of lung squamous cell carcinoma through transcriptionally upregulating NCK1 via interacting with MYC.

Zhou X, Bao W, Zhang D, Yang Y, Du X, Qiu G Cancer Biol Ther. 2021; 22(3):196-203.

PMID: 33629937 PMC: 8043171. DOI: 10.1080/15384047.2020.1842717.


The Regulatory Functions of lncRNAs on Angiogenesis Following Ischemic Stroke.

Gan L, Liao S, Xing Y, Deng S Front Mol Neurosci. 2021; 13:613976.

PMID: 33613191 PMC: 7890233. DOI: 10.3389/fnmol.2020.613976.